Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | MVD | P53602 | 3/20 | 0.34 |
| ▸ | FNTA | P49354 | 3/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149931 | 0.94 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.82 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL18714 | 0.82 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL3253186 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL21246913 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL25284822 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL9632051 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL22717549 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL3385312 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL897837 | 0.79 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108192696-B | Calcium carbonate whisker modified composite calcium sulfonate lubricating grease and preparation method thereof | 上海峰竺复合新材料科技有限公司 | 2020-09-01 | — | — | CN | claimed |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-01-24 | — | — | US | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| CN-117625106-A | High-temperature-resistant silver conductive adhesive and preparation method thereof | 宁夏中色新材料有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115180618-B | Preparation method of graphene nano-sheet composite powder and product | 哈尔滨工业大学（深圳） | 2023-10-20 | — | — | CN | disclosed |
| CN-115197540-B | Preparation method of modified epoxy composite material suitable for marine environment and product | 哈尔滨工业大学（深圳） | 2023-08-08 | — | — | CN | disclosed |
| CN-114085411-B | Embossing photoresist release film material with exhaust function and preparation method and application thereof | 金万正(广东)新材料有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2102217-A2 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008062379-A2 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | FDPS 3419/4885BLM 4616/4885TDP1 4163/4885 |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | PROC, CYP27B1, SLC46A1 | FDPS 1172/4885BLM 4028/4885TDP1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.